Exciting Leadership Changes at Recordati
Recordati has announced the appointment of Mike McClellan as its new Chief Financial Officer (CFO), effective January 1, 2026. This transition marks an exciting chapter for the company as they continue to establish a robust strategy in the healthcare market.
Mike McClellan: An Asset to Recordati
With nearly 30 years of experience in the pharmaceutical industry, Mike McClellan is no stranger to challenges and opportunities. His previous tenure as CFO at Almirall from 2019 to 2025 allowed him to drive growth and profitability, proving his capability in various roles across globally recognized companies. His leadership at Almirall included spearheading business development, launching key products, and connecting effectively with investors.
A Proven Track Record
Before Almirall, McClellan held several important roles at Teva Pharmaceuticals, where he made significant contributions as Group CFO and CFO of Global Specialty Medicines. His history at Sanofi includes serving as CFO for North America and Europe, alongside various country-level CFO positions. Such a breadth of experience positions him perfectly to lead Recordati's financial strategies.
Rob Koremans' Vision for the Future
Rob Koremans, the CEO of Recordati, expressed his enthusiasm for McClellan's addition to the team: “We are delighted to welcome Mike as our incoming CFO following a thorough search process. His expertise will be instrumental as we pursue our strategies for growth and business development.” This statement underlines the high expectations surrounding McClellan's role and the importance of strategic financial management in the pharmaceutical sector.
Focus on Stakeholder Engagement
As Recordati continues to expand, engaging all stakeholders will remain a priority. Koremans emphasized the need for meaningful interactions with investors and partners, which will be pivotal under McClellan's leadership.
Mike McClellan's Perspective
Sharing his excitement, McClellan stated, “I am truly pleased to join Recordati, a company with a strong track record of consistent financial performance.” His passion for the industry shines through as he looks forward to contributing to Recordati's journey and unlocking further potential.
Company Overview and Commitment
Recordati has a rich history rooted in family-run pharmacy operations dating back to the 1920s. The company is listed on the Italian Stock Exchange (XMIL: REC) and is active in over 150 countries, providing a wide range of pharmaceutical treatments for both specialty and primary care, including rare diseases.
The organization prides itself on its integrated operations, from clinical development to manufacturing and commercialization. The commitment to health as a fundamental right drives Recordati's mission, further emphasizing the company's dedication to delivering critical healthcare solutions. As they continue their trajectory of growth, attracting skilled leaders like McClellan becomes essential for fostering innovation and sustaining their great reputation in the marketplace.
Frequently Asked Questions
Who is the new CFO of Recordati?
Mike McClellan has been appointed as the new Chief Financial Officer of Recordati, starting January 1, 2026.
What is Mike McClellan's background?
McClellan has nearly 30 years of experience in the pharmaceutical industry, including significant roles at Almirall and Teva.
How does Rob Koremans view McClellan's appointment?
Rob Koremans expressed enthusiasm, stating that McClellan's expertise will be crucial as Recordati pursues growth and development strategies.
What is Recordati's mission?
Recordati's mission is centered around the belief that health is a fundamental right and aims to empower individuals to live life to the fullest.
In how many countries does Recordati operate?
Recordati operates in approximately 150 countries, offering a variety of pharmaceutical treatments.
